Skip to main content
TipRanks
Go Ultimate75% OFF

HCA Healthcare (HCA) AI Stock Analysis

1,849 Followers
HCA

HCA Healthcare

(NYSE:HCA)

Select Model
Rating:67Neutral
Price Target:$554.00â–²(16.49% Upside)
Action:reiterated
Date:11/05/26

The score is anchored by strong technical momentum and a constructive earnings outlook with resilient volumes and cost control. This is offset by elevated balance-sheet risk (high leverage and negative equity) and policy/payer-mix headwinds (exchange disenrollment and reduced Medicaid supplemental payments expected in 2027). Valuation is reasonable on P/E but offers limited support from a low dividend yield.

Positive Factors
Sustained Volume GrowthPersistent volume growth across admissions and emergency visits indicates durable demand for HCA’s services. Continued utilization supports revenue expansion, improves fixed-cost absorption, and gives the company a stronger foundation for sustaining earnings as capacity and market presence grow.
Negative Factors
High Leverage and Negative EquityHCA’s elevated debt and persistently negative equity reduce financial flexibility and increase sensitivity to weaker operating conditions or higher funding costs. Leverage may constrain future capital allocation and amplify the consequences of any sustained pressure on earnings or cash generation.

HCA Healthcare Key Performance Indicators (KPIs)

Adjusted EBITDA by SegmentHighlights profitability across different business units, providing insight into which segments drive earnings and where operational efficiencies or challenges lie.

-$1.00B$0.00$1.00B$2.00B$3.00B$4.00BMar 22Jun 22Sep 22Dec 22Mar 23Jun 23Sep 23Dec 23Mar 24Jun 24Sep 24Dec 24Mar 25Jun 25Sep 25Dec 25Mar 26Jun 26
Chart Insights

The operating groups delivered steady multi‑year EBITDA expansion (with typical Q4 strength), but the recent sequential pullback into early 2026 and a deeper, more volatile Corporate & Other drag show margins are under strain. Management attributes near‑term weakness to a concentrated payer‑mix shock from exchange disenrollment (a material EBITDA hit in Q2) partially offset by Medicaid supplemental payments; the company is leaning on cost‑resiliency programs and buybacks, so future upside depends on policy stabilization and successful execution of those savings initiatives.

Data provided by:The Fly

HCA Healthcare (HCA) vs. SPDR S&P 500 ETF (SPY)

-30%-20%-10%0%10%20%HCA-7.18%SPY+4.27%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
$99.34B
Dividend Yield
0.64%
Average Volume (3M)
1.36M
Price to Earnings (P/E)
15.7
Beta (1Y)
0.27
Revenue Growth
5.82%
EPS Growth
16.59%
Country
US
Employees
320,000
Sector
Healthcare
Sector Strength
51
Industry
Medical - Care Facilities

HCA Healthcare Business Overview & Revenue Model

Company Description

HCA Healthcare, Inc., operating through its subsidiaries, delivers a comprehensive array of healthcare services throughout the United States. The organization manages a network of general and acute care hospitals that provide a full spectrum of medic...

How the Company Makes Money

HCA makes money primarily by delivering healthcare services and being reimbursed for those services by third-party payers and patients. Its core revenue stream is patient service revenue generated when patients receive care at HCA facilities (e.g., a...

HCA Healthcare Earnings Call Summary

Earnings Call Date:Oct 27, 2026(Q3-2026)|% Change Since:2.22%|Next Earnings Date:Feb 02, 2027
Earnings Call SentimentPositive

The call was positive overall. HCA reported continued volume growth, improved revenue per admission, solid cost performance, strong cash flow, share repurchases, a strong balance sheet, and guidance toward the upper half of its 2026 ranges. These positives outweighed significant but acknowledged challenges from exchange-related payer-mix deterioration, declining elective surgical volumes, higher professional fees, and lower expected Medicaid supplemental payment benefits in 2027.

Positive Updates

Sustained Volume Growth
Third-quarter adjusted admissions on a same-facility basis grew 3%, compared with 2.3% year to date, marking the company's 22nd consecutive quarter of volume growth. Admissions increased 2.7%, equivalent admissions increased 3%, and ER visits increased 5.1%.

Negative Updates

Significant Exchange Volume Decline and Payer-Mix Pressure
Same-facility exchange equivalent admissions declined approximately 19% year over year, versus an estimated 15% to 16% decline, although exchange volume improved approximately 8% sequentially from the second to the third quarter of 2026. Patients losing exchange coverage migrated almost one-for-one to uninsured status, representing approximately 80% of uninsured volume growth. Uninsured volume rose to approximately 10.5% of total equivalent admissions from 8.5% a year earlier, and the payer-mix shift reduced adjusted EBITDA by approximately $400 million in the quarter.

Company Guidance

For 2027, HCA expects demand to remain strong, with volume growth forecasted to be 2% to 3%; it expects approximately $550 million to $650 million less in Medicaid supplemental payment net benefits, anticipates favorable cost performance primarily due to its ongoing enterprise wide resiliency program and operating leverage from expected volume growth, and anticipates earnings will be generally consistent with 2026. Beyond 2027, performance is expected to be more in line with long term growth targets, assuming the company moves past the most significant effects on payer mix from the exchanges, assumes no material policy changes beyond HR1, and strategic initiatives generate significant value. For 2026, guidance ranges were reaffirmed, with results currently expected to be in the upper half of those ranges; incremental net benefits from Medicaid supplemental payment programs are expected to be between $600 million and $800 million, while the full year unfavorable impact on adjusted EBITDA from payer mix shifts is expected to be at or slightly above the upper end of the range of previously updated guidance.

HCA Healthcare Financial Statement Overview

Summary

Operating performance is solid (Income Statement Score 74) with multi-year revenue growth and healthy profitability, and cash generation is positive (Cash Flow Score 61) though recently softer. The major offset is the balance sheet (Balance Sheet Score 28): rising debt and persistently negative equity reduce financial flexibility and raise risk if conditions tighten.

Income Statement

74Positive

Balance Sheet

28Negative

Cash Flow

61Positive
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue78.70B75.60B70.60B64.97B60.23B58.75B
Gross Profit17.07B31.37B28.68B25.58B23.18B22.49B
EBITDA15.90B15.60B13.90B12.72B13.29B14.25B
Net Income6.78B6.78B5.76B5.24B5.64B6.96B
Balance Sheet
Total Assets63.45B60.72B59.51B56.21B52.44B50.74B
Cash, Cash Equivalents and Short-Term Investments908.00M1.04B2.02B935.00M908.00M1.45B
Total Debt52.43B50.20B45.24B41.86B40.20B36.73B
Total Liabilities68.05B63.49B58.96B55.15B52.51B49.25B
Stockholders Equity-8.08B-6.03B-2.50B-1.77B-2.77B-933.00M
Cash Flow
Free Cash Flow5.97B7.69B5.64B4.69B4.13B5.38B
Operating Cash Flow11.17B12.64B10.51B9.43B8.52B8.96B
Investing Cash Flow-6.07B-4.99B-4.93B-5.32B-3.39B-2.64B
Financing Cash Flow-5.18B-8.55B-4.58B-4.09B-5.66B-6.66B

HCA Healthcare Technical Analysis

Technical Analysis SentimentPositive
Last Price475.57

Price Trends

50DMA459.71Positive
100DMA431.97Positive
200DMA443.86Positive

Market Momentum

MACD7.03Positive
RSI48.88Neutral
STOCH12.75Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HCA, the sentiment is Positive. The current price of 475.57 is below the 20-day moving average (MA) of 485.69, above the 50-day MA of 459.71, and above the 200-day MA of 443.86, indicating a neutral trend. The MACD of 7.03 indicates Positive momentum. The RSI at 48.88 is Neutral, neither overbought nor oversold. The STOCH value of 12.75 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HCA.

HCA Healthcare Risk Analysis

HCA Healthcare disclosed 62 risk factors in its most recent earnings report. HCA Healthcare reported the most risks in the "Legal & Regulatory" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Legal & Regulatory - Litigation, compliance, new legislation, and taxation risks

Latest Risks Added

3 New Risks
1.Failure to effectively manage change associated with our technology, resiliency and other initiatives, including with respect to the implementation of a new EHR platform, may adversely affect our business, services and results of operations.Q4, 2025
2.Our business and operations are subject to risks related to hurricanes, extreme weather events or other natural disasters.Q4, 2025
3.Third-party payer controls designed to reduce costs and other payer practices intended to decrease inpatient services, surgical procedure volumes or reimbursement for services rendered may reduce our revenues.Q4, 2023

HCA Healthcare Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

HCA against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
THCTHC87Outperform$20.98B7.5860.60%―6.23%136.09%
UHSUHS76Outperform$10.09B7.4419.54%0.45%8.00%13.14%
ENSGENSG75Outperform$10.30B25.5216.63%0.15%17.49%19.82%
EHCEHC70Outperform$12.98B20.6325.17%0.58%9.36%20.78%
HCAHCA67Neutral$96.16B15.71-100.45%0.64%5.82%16.59%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
CYHCYH42Neutral$227.05M6.00-2.51%―-7.84%-88.93%

* Healthcare Sector Average

Performance Comparison

-40%-20%0%20%HCACYHEHCTHCENSGUHSDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
HCA and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
HCAHca Healthcare475.57-22.07-4.43%
CYHCommunity Health Systems1.62-1.77-52.21%
EHCEncompass Health133.6521.3519.01%
THCTenet Healthcare Corp.263.1948.5722.63%
ENSGThe Ensign176.32-7.99-4.33%
UHSUniversal Health Services179.43-56.49-23.95%

HCA Healthcare Corporate Events

Private Placements and Financing

HCA Healthcare Announces Senior Notes Offering, Plans Redemption

Neutral
Nov 2, 2026

On November 2, 2026, HCA Healthcare announced that its direct, wholly owned subsidiary, HCA Inc., had commenced a proposed public offering of senior unsecured notes. The release said the notes’ maturity, interest rate and principal amount would be de...

Business Operations and StrategyStock BuybackDividendsFinancial Disclosures

HCA Healthcare posts solid Q3 results, maintains guidance

Positive
Oct 27, 2026

HCA Healthcare, Inc. is a large U.S.-based healthcare services provider that operates 189 hospitals and about 2,600 ambulatory sites of care, including surgery centers, freestanding emergency rooms, urgent care centers and physician clinics, across 1...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 05, 2026